Every material Form 8-K INTENSITY THERAPEUTICS, INC. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Intensity Therapeutics reported a third quarter 2026 net loss of $3.5 million, up from $2.7 million a year earlier, as research and development spending rose to $2.4 million. The company ended the quarter with $8.5 million in cash and cash equivalents and said it raised $1.5 million in net proceeds through its at-the-market facility during the quarter, while it resumed patient enrollment in two clinical trials.
Net loss was $3.5 million for Q3 2026, compared with $2.7 million for Q3 2025.
Research and development expenses were $2.4 million, compared with $1.6 million a year earlier, mainly due to higher INVINCIBLE-3 Study costs.
Cash and cash equivalents were $8.5 million as of September 30, 2026, down from $11.9 million at December 31, 2025.
The company raised $1.5 million in net proceeds under its $60 million at-the-market facility in Q3 2026.
Intensity Therapeutics reported a second quarter 2026 net loss of $3.0 million, up from $2.5 million a year earlier, with no revenue reported. Cash and cash equivalents were $9.5 million as of June 30, 2026, and the company said it restarted resources-dependent trial activity, including resuming enrollment at limited U.S. sites in the Phase 3 INVINCIBLE-3 study, which increased costs.
Net loss was $3.0 million for Q2 2026 versus $2.5 million for Q2 2025.
Research and development expenses rose to $1.8 million from $1.5 million, mainly from higher INVINCIBLE-3 study costs.
Cash and cash equivalents were $9.5 million on June 30, 2026, down from $11.9 million at December 31, 2025.
The company raised $1.6 million net under its at-the-market facility in Q2 2026 and $1.3 million more after June 30, 2026.
Intensity Therapeutics reported a first quarter 2026 net loss of $2.4 million, down from $3.3 million a year earlier, as research and development expenses fell to $1.2 million from $2.2 million. Cash and cash equivalents were $10.2 million at March 31, 2026, down from $11.9 million at December 31, 2025, and the company said it will resume enrollment in its INVINCIBLE-3 Phase 3 trial, which had been paused for funding reasons, by the third quarter of 2026.
Net loss was $2.4 million for the three months ended March 31, 2026, versus $3.3 million a year earlier
Research and development expenses were $1.2 million, down from $2.2 million, mainly due to lower INVINCIBLE-3 Study costs
General and administrative expenses rose to $1.3 million from $1.2 million, driven by an estimated bonus accrual
Cash and cash equivalents were $10.2 million at March 31, 2026, versus $11.9 million at December 31, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every INTENSITY THERAPEUTICS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →